155 related articles for article (PubMed ID: 38098005)
1. IL20RB signaling enhances stemness and chemotherapy resistance in pancreatic cancer.
Li XH; Huang GZ; Xu ZL; Zhao CY; Dong XY; Cui BK; Lin XJ
J Transl Med; 2023 Dec; 21(1):911. PubMed ID: 38098005
[TBL] [Abstract][Full Text] [Related]
2. FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF-β/SMAD3 signaling.
Zhang Z; Xu Y
Mol Med; 2022 Jul; 28(1):82. PubMed ID: 35854234
[TBL] [Abstract][Full Text] [Related]
3. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
[No Abstract] [Full Text] [Related]
4. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J
J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma.
Zhang H; Liu Y; Wang B; Wang C
BMC Genom Data; 2022 Jul; 23(1):58. PubMed ID: 35883015
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling.
Long J; Jiang C; Liu B; Dai Q; Hua R; Chen C; Zhang B; Li H
Cancer Lett; 2018 Jun; 423():113-126. PubMed ID: 29196128
[TBL] [Abstract][Full Text] [Related]
9. IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer.
He W; Wu J; Shi J; Huo YM; Dai W; Geng J; Lu P; Yang MW; Fang Y; Wang W; Zhang ZG; Habtezion A; Sun YW; Xue J
Cancer Res; 2018 Jun; 78(12):3293-3305. PubMed ID: 29572224
[TBL] [Abstract][Full Text] [Related]
10. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
[TBL] [Abstract][Full Text] [Related]
11. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
12. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
13. Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma.
Guo H; Jiang S; Sun H; Shi B; Li Y; Zhou N; Zhang D; Guo H
Dis Markers; 2022; 2022():9443407. PubMed ID: 35299868
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Asuthkar S; Stepanova V; Lebedeva T; Holterman AL; Estes N; Cines DB; Rao JS; Gondi CS
Mol Biol Cell; 2013 Sep; 24(17):2620-32. PubMed ID: 23864708
[TBL] [Abstract][Full Text] [Related]
15. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblasts promote the stemness of CD24
Li Y; Wang R; Xiong S; Wang X; Zhao Z; Bai S; Wang Y; Zhao Y; Cheng B
J Mol Med (Berl); 2019 Feb; 97(2):243-255. PubMed ID: 30564864
[TBL] [Abstract][Full Text] [Related]
17. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.
Hasegawa S; Eguchi H; Nagano H; Konno M; Tomimaru Y; Wada H; Hama N; Kawamoto K; Kobayashi S; Nishida N; Koseki J; Nishimura T; Gotoh N; Ohno S; Yabuta N; Nojima H; Mori M; Doki Y; Ishii H
Br J Cancer; 2014 Oct; 111(8):1572-80. PubMed ID: 25117811
[TBL] [Abstract][Full Text] [Related]
19. The m
Zhang Y; Liu X; Wang Y; Lai S; Wang Z; Yang Y; Liu W; Wang H; Tang B
Mol Cancer; 2022 Sep; 21(1):174. PubMed ID: 36056355
[TBL] [Abstract][Full Text] [Related]
20. Fzd7/Wnt7b signaling contributes to stemness and chemoresistance in pancreatic cancer.
Zhang Z; Xu Y; Zhao C
Cancer Med; 2021 May; 10(10):3332-3345. PubMed ID: 33934523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
